ESC 365 - Promise of epigenetic modulation as a target in atherosclerotic patients.

ESC Premium Access

Promise of epigenetic modulation as a target in atherosclerotic patients.

Session: Managing diabetes & cardiovascular disease (CVD): is epigenetics a new way forward? (EBAC Accredited)

Topic: Atherosclerosis

Speaker: Professor E. Stroes (Amsterdam, NL)

Organised by Physicians' Academy for Cardiovascular Education, supported with an educational grant by Resverlogix

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Erik Stroes

Academic Medical Centre, Amsterdam (Netherlands (The))

39 presentations

0 follower

4 more presentations in this session

Introduction - Managing diabetes & CVD: is epigenetics a new way forward?

Speaker: Professor L. Badimon (Barcelona, ES)

Managing high risk diabetes patient with cardiovascular disease: what works, and what else can we do?

Speaker: Professor R. Kausik

Insights from the first trials in epigenetics in human: what is the way forward?

Speaker: Professor S. Nicholls (Melbourne, AU)

Discussion - Managing diabetes & CVD: is epigenetics a new way forward?

Speaker: Professor R. Kausik

Access the full session

Managing diabetes & cardiovascular disease (CVD): is epigenetics a new way forward? (EBAC Accredited)

Speakers: Professor E. Stroes, Professor L. Badimon, Professor R. Kausik, Professor S. Nicholls, Professor R. Kausik

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources